机译:Rucaparib 治疗后转移性去势抵抗性前列腺癌患者 BRCA 逆转突变的出现
Translational Medicine Clovis Oncology Inc.;
Greenebaum Comprehensive Cancer Center University of Maryland;
Section of Hematology/Oncology Department of Medicine University of ChicagoHematology/Oncology Mayo ClinicMedical Oncology Department Hospital Universitario 12 de OctubreMedical Oncology Hospital Universitari Germans Trias i PujolMedical Oncology Cabrini HospitalGenitourinary Oncology H. Lee Moffitt Cancer CenterMedical Oncology CHU Sart Tilman University of LiègeMedical Oncology Comprehensive Cancer Centers of NevadaMedical Oncology Roswell Park Comprehensive Cancer CenterHematology/Oncology UT Southwestern Medical CenterHematology/Oncology Kaiser Permanente Oncology Clinical Trials ProgramDepartment of Drug Development and Innovation (D3i) Institut CurieBiostatistics Clovis Oncology Inc. BoulderClinical Development Clovis Oncology UK LtdClinical Operations Clovis Oncology Inc.Medical Oncology Guy's HospitalGenitourinary Oncology Service Memorial Sloan Kettering Cancer Center;
Acquired resistance; BRCA reversion mutations; Circulating tumor DNA; Metastatic castration-resistant prostate cancer; Next-generation sequencing; Poly(adenosine diphosphate-ribose) polymerase inhibitor;
机译:Re: Andrea Loehr, Arif Hussain, Akash Patnaik, et al. Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.09.010
机译:Reply to Feng Qi, Zicheng Xu, and Qing Zou's Letter to the Editor re: Andrea Loehr, Arif Hussain, Akash Patnaik, et al. Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.09.010
机译:BRCA Reversion Mutations in Metastatic Castration-Resistant Prostate Cancer
机译:mathematical models of androgen Resistance in prostate Cancer patients under Intermittent androgen suppression Therapy